Long COVID (LC) affects an estimated 5-10% of individuals with SARS-CoV-2 causing apersistent physical, cognitive, and functional impairment with potentially severesocioeconomic consequences. While RECOVER-Adult cycle 1 established the largest, mostcomprehensive U.S. adult LC cohort (14,730 participants), key questions remain aboutlong-term disease trajectories, biological mechanisms, and late-emerging complications.RECOVER-Adult cycle 2 will follow selected participants for two years each, focusing onneurocognitive, cardiopulmonary and infection-associated chronic conditions (IACC) suchas Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and autonomic dysfunction.Using a case-cohort design, the study will investigate disease persistence versusresolution, biological mechanisms, and onset of new chronic illnesses, generatingcritical insights to guide prevention, treatment, and public health policy.
Not Provided
Inclusion Criteria:
- RECOVER-Adult 2024 LCRI 11 or greater, as defined by Geng et al, 2024;1 or
- At least 1 RECOVER-Adult LCRI symptom and either a) poor quality of life (QoL) as
defined by a response of "poor" on the PROMIS-10 QoL question or b) "bother scale"
is "quite a bit" or "very much" for corresponding LCRI symptom; or
- At least 1 National Academies of Sciences, Engineering, and Medicine (NASEM) common
symptom and either a) poor QoL, or b) "bother scale" is "quite a bit" or "very much"
for corresponding NASEM symptom.
Exclusion Criteria:
- Individuals who have a known or documented hemoglobin lower than 8.5 g/dL,
- Individuals who have not yet reached the age of majority,
- Individuals who are unable to provide consent,
- Individuals who are unwilling to consent to biospecimen collection or are unwilling
to participate in the complete protocol, including all assessments and the cycle 2
visit schedule. Note that there are no exclusions related to blood volume
collection. For healthy adults, the volume of blood collected (70.9 mL per visit and
per year) is substantially lower than the federal minimal risk limit of 550 mL
within 8 weeks,
- Individuals in hospice care,
- Individuals with a serious medical condition which would prevent in-person
participation,
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families, unless enrolled only as
caregiver, or
- Long-term incarcerated individuals
NYU Langone Health
New York, New York, United States
Leora Horwitz, MD
646-501-2685
RECOVER_CSC@nyulangone.org
Priscilla Short, CIP, CCRP
RECOVER_CSC@nyulangone.org
Leora Horwitz, MD, Principal Investigator
NYU Langone Health